RKWD

ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|

Rockwood Research

REGN

REGENERON PHARMACEUTICALS, INC.

Pharmaceutical Preparations · SIC 2834CIK 872589Held by 8 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

i

11 of 11 reported changes in each tracked manager’s latest 13F vs its prior quarter (2 reporting periods). Every change is listed — no cap.

ManagerActionShare change% chgEnding % of 13F bookPosition size

Q2 2026Position history →

Add+412,899+9.3%1.6%$3.04B

Southeastern Asset Management

Q2 2026Position history →

Add+21,660+16.6%5.0%$0.09B

Renaissance Technologies

Q2 2026Position history →

Add+81,420+121.9%0.13%$0.09B

Bridgewater Associates

Q2 2026Position history →

Add+28,609+125.9%0.13%$0.03B

Q2 2026Position history →

Add+1,173+175.9%0.01%$<0.01B

Capital World Investors

Q2 2026Position history →

Trim(604,075)(42.6%)0.06%$0.51B

Sound Shore Management

Q2 2026Position history →

Trim(23,966)(15.9%)2.4%$0.08B

Adage Capital Management

Q2 2026Position history →

Trim(19,448)(18.9%)0.07%$0.05B

Capital Research Global Investors

Q2 2026Position history →

Exit(101,891)(100.0%)exited$0.08B

OrbiMed Advisors

Q2 2026Position history →

Exit(14,700)(100.0%)exited$0.01B

Scion Asset Management

Q3 2025Position history →

Exit(15,000)(100.0%)exited$0.01B

Changes compare each manager’s latest 13F with its prior quarter for the same CUSIP. “First observation” rows have no earlier stored filing to compare and are never counted as buys; “Split?” rows moved by a near-whole factor at an unchanged value and are treated as stock splits, not trades. Ending weight is the position after the change, not the size of the change.